• Tissue Repairs pockets second US patent
  • Clarity Pharma starts recruitment in Phase 2

 

Tissue Repair (ASX:TRP) announced the granting of a second US patent for the use of TR-987 and Glucoprime on any skin condition – including burns, chromic wounds, surgical wounds, pressure ulcers, and any post-procedure wounds, both surgical or cosmetic.

This patent follows the first one granted in April, which has claims on the method of manufacturing of Glucoprime.

Glucoprime is the API (active pharmaceutical ingredient) used in formulating TR-987 in leg ulcers.

Glucoprime is also used in TRPro+, which is a product for post-operative cosmeceutical application in a number of dermatological and related treatments.

There are currently no known alternative processes from which to produce this proprietary biological polysaccharide molecule.

Tissue Repair is one of a number of biotechs globally seeking to enter a Phase 3 program in venous leg ulcers.

If the trials for TR-987 are successful, it will be the first drug approved for venous leg ulcers in over 25 years where there is now a large and growing market.

“The patent is significant as it provides broad protection for the use of our proprietary Glucoprime technology across its current dual focus of chronic wounds and post procedure cosmetic healing,” said TRP’s co-founder and Executive Director, Tony Charara.

“It also extends protection into any topically applied skin condition, such as pressure ulcers, diabetic foot ulcers, surgical wounds and burns.”

 

Tissue Repair share price today:

 

Clarity Pharma starts Phase 2 recruitment

Clarity Pharma (ASX:CU6) reported that its US-based diagnostic 64Cu SAR-Bombesin trial (SABRE) for patients with PSMA-negative prostate cancer is now open for recruitment.

SABRE is a Phase 2 Positron Emission Tomography (PET) imaging trial of participants with PSMA-negative biochemical recurrence (BCR) of prostate cancer following therapy.

It’s a multi-centre, single arm, non-randomised, open-label trial of 64Cu-labelled SAR- Bombesin in 50 participants.

The primary objectives of the trial are to investigate safety and tolerability of the product, as well as its ability to correctly detect recurrence of prostate cancer.

Clarity has been investigating Bombesin for many years, and believe it is an agent with high diagnostic and therapeutic potential.

“In addition to investigating the clinical benefits of the product, we also look forward to leveraging centralised manufacture and on-demand delivery advantages of copper-based products,” said Dr Andrei Iagaru, Lead Principal Investigator in the SABRE trial.

“ These features have potential to facilitate universal access to SAR-Bombesin and enhance accessibility to treatment facilities throughout the US,” he added.

The SABRE trial reinforces Clarity’s strategy to run clinical trials for first approvals in the US under clinical protocols which have been reviewed by the US FDA.

 

Clarity Pharma share price today:

Read MoreBiotech

Featured Companies

You might be interested in